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Exposure to pro-inﬂammatory cytokines, such as Angiotensin II, endothelin-1 or TNF leads to endo-
thelial dysfunction, characterized by the reduced production of nitric oxide via endothelial nitric
oxide synthase (eNOS). We recently identiﬁed the Ca2+ binding protein S100A1 as an essential factor
required for eNOS activity. Here we report that pro-inﬂammatory cytokines down-regulate expres-
sion of S100A1 in primary human microvascular endothelial cells (HMVECs) via induction of micr-
oRNA-138 (miR-138), in a manner that depends on the stabilization of HIF1-a. We show that loss of
S100A1 in ECs reduces stimulus-induced NO production, which can be prevented by inhibition of
miR-138. Our study suggests that targeting miR-138 might be beneﬁcial for the treatment of cardio-
vascular disease.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction as a shift towards a chronic pro-coagulative and vaso-constrictiveDysfunction of the arterial vascular endothelium is associated
with the most signiﬁcant predisposing risk factors for cardiovascu-
lar disease (CVD) such as smoking, hypertension, diabetes, hyper-
glycemia, hypercholesterolemia and advanced age [1]. The
endothelium serves a source of vasoactive factors that maintain –
in its healthy state – the endothelium’s anti-inﬂammatory,
anti-thrombotic, anti-proliferative, and stimulus-dependent
vasodilatory functions. Induction of chronic vascular inﬂammation,
as characterized by the persistent elevation of circulating inﬂam-
matory cytokines, correlates with endothelial dysfunction (ED)
and is recognized as a major contributor to the development of
atherosclerosis and cardiovascular disease [2–4]. ED can be seenstate that correlates with, but typically precedes, clinical manifes-
tations of coronary, cerebrovascular and peripheral vascular dis-
eases [1,5]. Central to the quiescent state of healthy endothelium
is the stimulus-dependent generation of the vaso-relaxant factor
nitric oxide (NO) by the endothelial isoform of the nitric oxide syn-
thase enzymes (eNOS, NOS3). Chronic elevation of pro-inﬂamma-
tory cytokines, most notably Angiotensin II leads to a reduction
in stimulus-induced NO release from the endothelium with a con-
sequent loss of vasoreactivity [6].
S100A1 is a small EF-hand Ca2+ binding protein that relays intra-
cellular Ca2+ oscillations and regulates vascular tone [7–10]. Previ-
ously, we were able to show that S100A1 directly interacts with
eNOS, prevents PKC-mediated phosphorylation of the eNOS inhibi-
tory Thr-495 site and augments eNOS enzymatic activity in ECs
[11]. S100A1 levels are rapidly lost in hypoxic ECs or in ischemic tis-
sues and this correlates with a loss of stimulus-induced NO produc-
tion [11]. We recently published that endothelial cell-type speciﬁc
regulation of S100A1 in response to hypoxia is achieved via the
HIF1-a dependent induction of miR-138, which speciﬁcally targets
a conserved 22 nucleotide sequence in the 30UTR of S100A1. Pro-
inﬂammatory cytokines have been shown to activate HIF1-a in a
variety of different cells types important to vascular biology
[12–17]. Thus, here we sought to investigate if pro-inﬂammatory
cytokines cause loss of eNOS activity and lead to ECs dysfunction
A. Sen et al. / FEBS Letters 588 (2014) 906–914 907via HIF1-a mediated induction of miR-138 and consequent loss of
S100A1.
2. Materials and methods
2.1. Cell culture
EA.hy926 endothelial cells ATCC (CRL-2922) were cultured in
DMEM (4.5 g/L glucose) supplemented with 10% FBS. Human
microvascular endothelial cells (HMVEC) were purchased from
Lonza (CC-7030) at passages 4–5 and cultured in ATCC vascular
cell basal medium (PCS-100-030) supplemented with the ATCC
endothelial cell VEGF growth kit (PCS-100-041). For chemical hy-
poxia cells were treated for 24 h with CoCl2 (250 lmol/L). Viabil-
ity of EA.hy926 ECs or primary human ECs was not
compromised at CoCl2 concentrations less than 1 mmol/L for
24 h (not shown). Where appropriate cells were incubated with
Ang II (10 nmol/L), Et-1 (10 nmol/L) or TNFa (50 ng/ml) for the
times indicated.
2.2. Immunoblot assay
Cell samples were lysed in Laemmli buffer and 30 lg/Lane
whole cell extract was loaded on 4–20% Tris–Glycine gel, (Life
Technologies, CA) and transferred to nitrocellulose membrane.
Membranes were probed for S100A1 (Acris, San Diego, CA, cat #
SP5355P, b-actin (SantaCruz cat # sc-8432), HIF1-a (SantaCruz
cat # sc-10790) total eNOS (BD Biosciences cat # 610297) or phos-
pho Thr-495 eNOS (BD Biosciences cat # 612707). Protein expres-
sion was quantitatively assessed using an Odyssey scanner (Li-Cor
Biosciences, Lincoln NE). All immunoblot assays were done in
duplicate and repeated a minimum of 3 times.
2.3. Plasmids
All constructs were as described [18]. The S100A1-30UTR re-
porter construct of comprised the 30UTR of the human S100A1
gene cloned downstream of a constitutive ribosomal protein L10
(RPL10) promoter and renilla luciferase gene. A 30UTR control
plasmid with SV40 T antigen 30UTR and b-actin control plasmid
with b-actin promoter were used as controls for transfection efﬁ-
ciency. A gene block (IDT) comprising the entire S100A1-30UTR,
but lacking speciﬁcally the 22 nucleotide putative miR-138 target
site, was subcloned NheI to XhoI into the luciferase reporter vec-
tor to generate the DmiR-138 construct as described [18]. All con-
structs were veriﬁed by sequencing using Jefferson’s genomics
facility.
2.4. Transfection
EA.hy926 ECs were cultured in 24 well plates in DMEM with
10% FBS. Cells were transfected with 1 lg of luciferase reporter
constructs mixed with Lipofectamine 2000 in serum-free DMEM,
according to the manufacturer’s instruction (Life Technologies).
Transfection media was changed after 2–3 h and replaced with
DMEM, 10% FBS. Cells were harvested 40 h after transfection.
HIF1-a siRNA was purchased from SantaCruz (Dallas, TX, cat #
SC-35561). To inhibit activity of microRNA-138, we used a choles-
terol-conjugated antagomir-138 (10 lg/ml, Fidelity Systems,
Gaithersburg, MD) [19] to inhibit miR-138. To test activation of
MAPKs via miR-138, primary HMVECs were transfected in DMEM
with 20 nmol (per well of a 6-well dish) microRNA mimic
(Dharmacon ThermoFisher, cat # C-300605-05-0005) or Control
mimic (cat # CP-004500-01-05) using Lipofectamine 2000 and
media was changed after 1–2 h. Cell extracts were prepared
24 h later.2.5. Real time PCR for miR-138 expression
RNA was isolated from cell samples using RNAzol RT according
to manufacturer’s instruction (MRC, Inc cat # RN190). 1 lg of input
RNA was used to reverse transcribe cDNA using Origene (Rockville,
MD) kit (cat # HP100042). Human miR-138 real time PCR primer
pair (cat # HP300151) was from Origene which consisted of an uni-
versal primer-50-CTCTATGCGTCTGTACAAG-30 and microRNA-138
speciﬁc primer 50-AGCUGGUGUUGUGAAUCAGGCCG-30. Quantita-
tive real time PCR was performed using BioRad (Hercules, CA) SYBR
Green master mix and a Stratagene (La Jolla, CA) real time PCR cy-
cler. Expression of U6 RNA, which did not change by cytokine treat-
ment, was used to normalize for input RNA. In order to allow for
better comparison between different batches of primary HMVECs
the maximum expression of miR-138 induced by 24 h treatment
with Ang II (10 nmol/L) in HMVECs was arbitrarily set as 1.
2.6. Luciferase assays
Light Switch luciferase assay reagents (cat # LS100) were from
SwitchGear Genomics. ECs were cultured and transfected in 24
well plates. To measure luciferase expression, 100 ll of assay re-
agents were added to each well and enzyme activity was mea-
sured, according to the manufacturer’s instruction (SwitchGear
Genomics) using aWallac Victor3 Multilabel counter (Perkin Elmer,
MA). Luciferase expression is given as relative light units (RLU). All
luciferase experiments were done in triplicate and repeated a min-
imum of 3 times.
2.7. Matrigel tube formation assay
Growth-factor reduced Matrigel Matrix (BD Biosciences, cat #
356231) was diluted 1:1 with ATCC vascular cell basal medium
(no additives). HMVEC (approx 200000 cells) were treated with
Angiotensin II (10 nmol/L) and either incubated with antagomir-
138 or control or infected with recombinant adenovirus expressing
S100A1 and GFP from a bicistronic insert [10] or control (ctr) as de-
scribed [18] at a multiplicity of infection (MOI) of 17. After 24 h
cells were detached from the plastic support with trypsin and
seeded onto the Matrigel matrix in ATCC medium supplemented
with ATCC endothelial cell VEGF growth kit (PCS-100-041) and
Ang II (10 nmol/L). Images were taken 24 h later and digitized
using NIH-ImageJ software. Original images of the matrigel tube
formation assays are included as online Supplemental Fig. S11.
2.8. Nitric oxide assay
HMVEC (approx 100000 cells) were incubated with antagomir-
138 or control and either Ang II (10 nmol/L) or TNFa (50 ng/ml) for
24 h. Following this, cells were starved for 4 h in ATCC vascular cell
basal medium without supplements. Cells were then incubated
with ATCC vascular cell basal medium supplemented with all com-
ponents of the ATCC endothelial cell growth kit (PCS-100-041) ex-
cept VEGF. NO production was then stimulated with the addition
of 50 ng/ml VEGF (R&D systems) and Ang II or TNFa. Medium
was collected 24 h later and NO levels were measured using a ﬂuo-
rescent NO/Nitrite/Nitrate assay (Cayman Chemical, cat # 780051)
according to manufacturer’s instructions. In other experiments
HMVECs were infected with recombinant Adenovirus expressing
S100A1 and GFP from a bicistronic insert, or control, at a MOI of
17. The infection medium was removed 8 h later and incubation
was continued overnight. Next day cells were treated with Ang II
(10 nmol/L) or TNFa (50 ng/ml). After 24 h cells were starved for
4 h in ATCC medium without supplements. Cells were then
incubated with ATCC vascular cell basal medium supplemented
with all components of the ATCC endothelial cell growth kit
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with the addition of 50 ng/ml VEGF (R&D systems) and Ang II or
TNFa. Medium was collected 24 h later and NO levels were mea-
sured using a ﬂuorescent NO/Nitrite/Nitrate assay (Cayman Chem-
ical, cat # 780051) according to manufacturer’s instructions.
2.9. Statistical analysis
One-way ANOVA with Tukey’s post-test for multiple compari-
sons was used to analyze the appropriate data using GraphPad
PRISM software. Data are shown as ± S.E.M. in the ﬁgures. A P value
of <0.05 was considered statistically signiﬁcant. Experiments wereCoCl2untr. Ang II
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Fig. 1. Pro-inﬂammatory cytokines reduce S100A1 expression and cause dysfunction in
TNFa (50 ng/ml) or CoCl2 (250 lmol/L) for 24 h before extract preparation and SDS–PAG
repeated twice more, for quantiﬁcation see Fig. S1. (B) HMVECs were incubated with cyto
produced nitric oxide levels in the supernatant were measured using a nitrate/nitrite
infected with recombinant adenovirus expression S100A1 (or ctr. Adenovirus) and treate
with VEGF (50 ng/ml) for 24 h before assaying supernatant nitrate/nitrite levels. ⁄
untreated + VEGF. Experiment was performed 3 times, each at least in duplicate.done independently a minimum of 3 times. Each set-up was done
at least in duplicate for each repetition.
3. Results
3.1. Pro-inﬂammatory cytokines reduce S100A1 expression and cause
dysfunction in ECs
Endothelial cells isolated from patients with Heart Failure (HF)
display reduced levels of S100A1 [10], while increased expression
of vasoactive pro-inﬂammatory cytokines is known to correlate
with HF [20,21]. In order to investigate if pro-inﬂammatoryEt-1 TNF
S100A1
ICAM1
β-actin
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*
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ECs. (A) Primary HMVECs were incubated with Ang II (10 nmol/L), Et-1 (10 nmol/L),
E analysis for ICAM and S100A1. Representative image is shown. Experiment was
kines for 24 h, then treated ± VEGF (50 ng/ml) as indicated, for a further 24 h. eNOS
assay. Experiment was done 3 times, each at least in duplicate. (C) HMVECs were
d for 24 h with Ang II, Et-1 or TNF as indicated. Cells were then stimulated, or not,
P < 0.05 vs untreated, no VEGF. #P < 0.05 vs untreated, no VEGF; zP < 0.02 vs
A. Sen et al. / FEBS Letters 588 (2014) 906–914 909cytokines would change expression of S100A1 we treated primary
human microvascular endothelial cells (HMVECs) with Angioten-
sin II (Ang II), endothelin-1 (Et-1) or tumor necrosis factor (TNFa)
for 24 h. All of these cytokines reduced S100A1 protein levels to
less than 25% of untreated controls, while simultaneously increas-
ing expression of the intercellular adhesion molecule-1 (ICAM-1), a
molecule known to participate in vascular pathologies by promot-
ing the attachment of leucocytes to injured endothelium [22,23]
(Fig. 1A, see Fig. S1 for quantiﬁcation of Immunoblot). The magni-
tude of the effect was comparable to that induced by hypoxia (in-
duced by treatment with CoCl2) in ECs, a treatment we have
recently shown to cause EC dysfunction via the reduced expression
of S100A1 [18].
Reduced bioavailability of nitric oxide (NO) is a hallmark of
cytokine-induced EC dysfunction [24]. We have previously shownHIF
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Fig. 2. Pro-inﬂammatory cytokines decrease S100A1 via increased HIF1-a and miR-138
(250 lmol/L) for 24 h before extract preparation and SDS–PAGE analysis for HIF1-a.
quantiﬁcation see Fig. S2. (B) Expression levels of miR-138 were assessed by qPCR in
Endothelin-1 (Et-1, 10 nmol/L) or human TNFa (TNF, 10 ng/ml). Expression levels of th
cytokine treatment. ⁄P < 0.05 vs untreated. The experiment was performed 4 times, ea
luciferase reporter construct or the miR-138 binding site deleted reporter (D-miR-138)
untreated. Experiment was done 3 times, each in triplicate. (D) EA.hy926 ECs were transfe
siRNA against HIF1-a (Dharmacon) or scramble control and subsequently treated with
response was included as a control. ⁄P < 0.02 vs untreated. Experiment was done 3 timethat S100A1 is an essential regulator of eNOS (NOS3) activity in ECs
[11] and that lack of S100A1 impairs endothelial NO production
and endothelial-dependent vasodilation [10]. Treatment of
HMVECs with Ang II, Et-1 or TNFa all strongly impaired both basal
as well as stimulus-induced NO production (Fig. 1B). Re-expression
of S100A1 via infection with recombinant adenovirus restored both
basal as well as VEGF-induced NO production in cytokine-treated
ECs, demonstrating the essential role of S100A1 to eNOS activation
(Fig. 1C).
3.2. Pro-inﬂammatory cytokines decrease S100A1 via increased HIF1-
a and miR-138 levels in HMVECs
We recently reported that hypoxia-induced HIF1-a stabilization
in ECs led to the induction of miR-138 with consequent loss of1-α
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Fig. 3. Inhibition of miR1-38 restores normal function to cytokine-treated ECs. (A) EA.hy926 ECs were transfected with the S100A1-30UTR luciferase reporter construct and
incubated with either antagomir-138 or control and stimulated for 24 h with cytokines or CoCl2 as indicted prior to luciferase assay. ⁄P < 0.02 vs untreated. (B) Primary
HMVECs were treated with Ang II ± antagomir-138 for times indicated and S100A1 and phospho-T495 eNOS levels were assessed by Immunoblot analysis. b-Actin was
assessed as loading control. Representative images are shown. Experiment was repeated twice more, for quantiﬁcation see Fig. S9. (C) HMVECs were incubated with cytokines
for 24 h and co-incubated with either antagomir-138 or control, then treated ± VEGF (50 ng/ml) as indicated for a further 24 h. eNOS produced nitric oxide levels in the
supernatant were measured using a nitrate/nitrite assay. ⁄P < 0.05 vs untreated. #P < 0.05 vs untreated, no VEGF; zP < 0.05 vs untreated + VEGF. Experiment was performed 3
times, each at least in duplicate. (D) Primary HMVEC were incubated with antagomir-138 or control and treated with Ang II for 24 h. Next day later cells were infected
(MOI = 17) with either control Adenovirus or Adenovirus expressing S100A1. 24 h later cells were seeded onto Matrigel matrix. Images of EC tube formation were taken 24 h
later and digitized using Image J (Original pictures of EC tube formation are included as Supplemental Fig. S11. Representative images are shown. The experiment was done 3
times, each in duplicate.
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A. Sen et al. / FEBS Letters 588 (2014) 906–914 911S100A1 [18]. Ang II as well as Et-1 and TNF have been shown to in-
crease the stability of HIF1-a in different cell types, [25–27] albeit
not primary human ECs. All three different cytokines tested in-
creased HIF1-a levels (Fig. 2A, see also Fig. S2 for quantiﬁcation)
in HMVECs, comparably to those induced by chemical hypoxia
via CoCl2, and greatly induced miR-138 (Fig. 2B), (see Fig. S3 for
a timecourse of miR-138 induction in ECs). The importance of
the HIF1-a–miR-138 axis to the expression of S100A1 in ECs was
demonstrated by measuring expression of a luciferase reporter
construct that contained the human S100A1-30untranslated region
(30UTR) [18] in cytokine treated EA.hy926 cells, which are easily
transfectable, immortalized human endothelial cells. Expression
of this reporter construct was greatly diminished when cells were
exposed to Ang II, Et-1 or TNF (Fig. 2C) whereas expression of a
control construct having the 30UTR of the SV40-T-ag instead of
S100A1 was not affected by cytokine treatment (Fig. S4). The 30UTR
of the S100A1 mRNA has a strong miR-138 binding site [18]. Dele-
tion of the 22 nucleotide miR-138 target site within the S100A1-
30UTR also completely prevented any downregulation of reporter
gene expression by cytokine treatment (Fig. 2C). Finally, siRNA
mediated knockdown of HIF1-a reduced miR-138 expression in
Ang II treated ECs (Fig. S5) As expected, this inhibition of HIF1-a
by siRNA knockdown restored expression of the S100A1-30UTR re-
porter construct in cytokine or CoCl2 treated cells (Fig. 2D), while
expression of a control 30UTR luciferase reporter was not changed
by HIF1-a inhibition (Fig. S6).
3.3. Inhibition of miR-138 restores normal function to cytokine-treated
ECs
The importance of miR-138 to cytokine-induced EC dysfunction
was also demonstrated by direct inhibition of miR-138. When miR-untreated 15mAng II
Antag-138
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+
p-p38
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β
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Fig. 4. Inhibition of miR-138 prevents chronic activation of cytokine-induced MAPK ph
times indicated and the phosphorylation state of the MAPK p38 and ERK1/2 were asse
repeated twice more, for quantiﬁcation see Fig. S12. (B) Primary HMVECs were treated
phosphorylation state of the MAPK p38 and ERK1/2 were assessed by Immunoblot an
quantiﬁcation see Fig. S14.138 function was silenced by incubation of cytokine-treated ECs
with a cell-permeable, cholesterol-conjugated antimir (antago-
mir-138) [18] expression of a luciferase S100A1-30UTR reporter
gene was restored to normal (Fig. 3A) in a dose dependent fashion
(Fig. S7), while expression of a control-30UTR was unaffected
(Fig. S8). Moreover, the antagomir-138 restored normal S100A1
protein expression levels to cytokine-treated HMVECs (Fig. 3B).
We had previously shown that loss of S100A1 reduced NO produc-
tion by ECs via the increased phosphorylation of eNOS on Thr495
[11], a known inhibitory site [28]. Incubation of Ang II treated
HMVECs with the antagomir-138 reduced the increased phosphor-
ylation of eNOS pT495 within 5 h (Fig. 3B, see Fig. S9 for quantiﬁ-
cation of immunoblots), and was able to restore both basal as well
as VEGF-stimulated NO production in cytokine-treated HMVECs
(Fig. 3C) and reduced expression levels of ICAM back to normal
(Fig. S10). In addition, using the EC tube formation assay on matri-
gel matrix, we were able to show that both inhibition of miR-138
with the antagomir-138, as well as restoration of S100A1 levels
by recombinant adenovirus, was sufﬁcient to restore tube forma-
tion capability to Ang II treated HMVECs. (Fig. 3D, original, non-
digitized images are provided as Fig. S11).
3.4. Inhibition of miR-138 prevents chronic activation of cytokine-
induced MAPK phosphorylation
We next investigated the effects of miR-138 inhibition on cyto-
kine signal transduction. As might be expected from the time-
course of miR-138 induction, activation of the immediate,
receptor proximal, signal transduction cascades are unimpeded
by the inhibition of miR-138. Thus the MAPKs p38 and ERK1/2
are both rapidly and strongly activated by treatment of HMVECs
with Ang II (Fig. 4A, see Fig. S12 for quantiﬁcation). However,in 24h
+
+ +
+ +
5h 24h
+     +     
osphorylation. (A) Primary HMVECs were treated with Ang II ± antagomir-138 for
ssed by Immunoblot analysis. Representative images are shown. Experiment was
with Ang II ± antagomir-138 ± L-NAME (NOS inhibitor) for times indicated and the
alysis. Representative image is shown. Experiment was repeated twice more, for
912 A. Sen et al. / FEBS Letters 588 (2014) 906–914continued activation of MAPKs by Ang II at later timepoints (i.e.
post 5 h) was strongly dependent on miR-138, as treatment with
the antagomir-138 completely prevented phosphorylation of p38
and ERK1/2 at 5 h and 24 h. Moreover, incubation of HMVECs with
a miR-138 mimic for 24 h also led to MAPK activation, even in the
absence of cytokine treatment (Fig. S13). The reduction of this late
MAPK activation by miR-138 inhibition was due to the restoration
of eNOS activity, since incubation with the NOS-inhibitor L-NAME
increased the phosphorylation of both p-p38 and p-ERK, even in
the presence of the miR-138 inhibitor (Fig. 4B, see Fig. S14 for
quantiﬁcation).
4. Discussion
Chronic vascular inﬂammation is recognized as signiﬁcantly
predisposing to the development of cardiovascular disease. This
condition correlates with reduced bioavailability of cardioprotec-
tive NO and consequent diminished endothelium-dependent dila-
tion leading to a chronic pro-coagulative and vaso-constrictive
state. The most salient ﬁnding of our work here is the identiﬁcation
of a signaling cascade (Fig. 5) whereby vasoactive or pro-inﬂamma-
tory cytokine signaling increases stability of HIF1-a, induces miR-
138 expression that leads to loss of S100A1 and consequent
inactivation of eNOS. This signaling axis induces and maintains
the reduced bioavailability of NO, characteristic of the dysfunction
observed in ECs chronically exposed to vasoactive cytokines, such
as Ang II, Et-1 or TNF [29–35].
A large number of regulatory factors have been identiﬁed that
control the activity of eNOS (see Ref. [24] for a recent review).
Aside from the required cofactors Heme, NADPH, FAD, FMN, andHIF1 −α
AAAAAAAA
S100A1 
mRNA
MiR-138
Ang II or Et-1
pT495-
?
1
2
3
Endo
eNOS
Fig. 5. Proposed model of cytokine induced, miR-138-mediated, EC dysfunction (1). Eng
ligands leads to stabilization of HIF1-a in ECs through as yet incompletely deﬁned mec
S100A1 mRNA or suppress its translation, leading to rapid loss of S100A1 protein in E
reduction of NO generation (6). This loss of endothelial NO generation engenders endotBH4 [36–40], Ca2+/calmodulin (CaM) serves to enhance the cata-
lytic activity of eNOS in response to Ca2+ oscillations [41].
S100A1, belonging to the same EF-hand Ca2+ binding protein fam-
ily as CaM, also directly interacts with eNOS and serves as a
required cofactor, as we have recently shown [11]. Not surpris-
ingly, S100A1 deﬁcient mice display reduced stimulus-induced
endothelium-dependent vasorelaxation and are hypertensive
[10,42], similar to eNOS deﬁcient mice [43,44].
Activity of eNOS is enhanced by increased Ser-1177 phosphor-
ylation by Akt [45], and possibly other kinases [24] and decreased
by phosphorylation of Thr-495 [28]. Pointing towards a mecha-
nism revealing how S100A1 may control eNOS activity, we have
shown that siRNA knockdown-induced loss of S100A1 in ECs leads
to increased PKC activity and phosphorylation of eNOS on the
inhibitory Thr-495 site, with resultant loss of stimulus-induced
NO generation [11].
Overall expression levels of S100A1 are down-regulated in sev-
eral pathologies linked to tissue malperfusion. Patients in heart
failure [9], as well as those with critical limb ischemia [11] show
reduced myocardial and gastrocnemius muscle S100A1 levels,
respectively. The ECs of these tissues appear especially susceptible
to hypoxia-induced loss of S100A1 [11]. We recently identiﬁed
miR-138 as the hypoxia-induced negative regulator of S100A1 in
microvascular ECs [18]. In this cell type, the rapid induction of
miR-138 by hypoxia critically depends on the stabilization of
HIF1-a [18]. Although most prominently regulated by the action
of oxygen-sensing prolylhydroxylases (PHDs), stability of the lim-
iting a-subunit of HIF1 can also occur under normoxic conditions
(see [46] for review), and has been demonstrated in response to
pro-inﬂammatory cytokines, including Angiotensin II and TNF inS100A1 
protein
TNF
eNOS NO
4
5
6
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agement of vasoactive or pro-inﬂammatory cytokine receptors by their respective
hanisms (2). Stabilization of HIF1-a increases miR-138 levels (3), which destabilize
Cs (4). This leads to increased phospho-Thr495 eNOS levels (5) with consequent
helial dysfunction (7).
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ECs [25]. Here we ﬁnd that at least 3 different vasoactive pro-
inﬂammatory cytokines (Ang II, Et-1 and TNF) are able to increase
stability of HIF1-a in primary human microvascular ECs with con-
sequent induction of miR-138, followed by down-regulation of
S100A1 and resultant loss of eNOS activity.
We found that even basal NO generation in HMVECs is strongly
reduced upon cytokine treatment, with complete loss of stimulus-
induced NO generation (Fig. 1B), while inhibition of miR-138 re-
stores normal S100A1 expression to HMVECs (Fig. 3B) and, in turn,
is capable of restoring both basal and VEGF-induced levels of NO
generation to HMVECs (Fig. 3C). This occurs even in the continued
presence of cytokines, and coincides with reduced phosphorylation
of the inhibitory Thr-495 site of eNOS (Fig. 3B), an event we have
shown to correlate with restored S100A1 function in ECs [18].
Finally our study demonstrates the importance of miR-138 in-
duced loss of S100A1, and subsequent eNOS inhibition, to the
maintenance of cytokine-induced pro-inﬂammatory signal trans-
duction in ECs. While, as expected, the immediate Angiotensin II-
induced activation of the MAPKs p38 and ERK1/2 is not impacted
by inhibition of either miR-138 (via antagomir-138) or eNOS (via
L-NAME), the long term (post 5 h) activation of these signaling
intermediates is dependent upon the inactivation of eNOS brought
on by the miR-138 induced loss of S100A1, as phosphorylation of
ERK1/2 or p38 is abrogated at these later timepoints upon miR-
138 inhibition but restored when eNOS is inhibited (Fig. 4B). These
studies may provide an explanation for the deleterious effects of
chronic, rather than acute, cytokine exposure in ECs.
Taken together our study provides a compelling rationale to fur-
ther investigate the therapeutic potential of selective miR-138
inhibition for the treatment of cardiovascular pathologies linked
to endothelial dysfunction.
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